<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288495</url>
  </required_header>
  <id_info>
    <org_study_id>Long Term Fructose</org_study_id>
    <nct_id>NCT01288495</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial of L-Alanine and Placebo in Fructose Intolerance</brief_title>
  <official_title>Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance: a Double-blind, Randomized Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <brief_summary>
    <textblock>
      Data suggest that alanine may facilitate the intestinal absorption of fructose in patients&#xD;
      with DFI and thereby may decrease GI symptoms.&#xD;
&#xD;
      We hypothesize that the ingestion of supplemental L-alanine along with mixed meals or snacks&#xD;
      that contain foods with free fructose or high fructose content will decrease GI symptoms in&#xD;
      subjects with dietary fructose intolerance by facilitating intestinal absorption of fructose.&#xD;
&#xD;
      Aim: To investigate the effects of co- administration of equi-molar doses of L-alanine or&#xD;
      placebo on the occurrence of GI symptoms in subjects with dietary fructose intolerance, in a&#xD;
      randomized, double blind, cross over study.&#xD;
&#xD;
      Methods: We propose to investigate the effects of co-administration of equi-molar doses of&#xD;
      L-alanine or placebo on the occurrence of GI symptoms in 70 subjects with dietary fructose&#xD;
      intolerance, in a randomized, double blind, cross over study.&#xD;
&#xD;
      Data Analysis: The primary outcome measure will be a comparison of baseline breath sample&#xD;
      values and study visit breath sample values. Additionally, we will assess subject-reported&#xD;
      occurence and severity of nine gastrointestinal symptoms during the test on a visual analog&#xD;
      scale (VAS).&#xD;
&#xD;
      Expected Results: We anticipate that dietary fructose intolerance (DFI) symptoms will improve&#xD;
      with ingestion of supplemental L-alanine (along with foods containing free fructose or high&#xD;
      fructose content). We additionally expect treatment of DFI with administration of L-alanine&#xD;
      powder to be more practical than co-ingestion of alanine-rich foods, and more convenient for&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI moved institutions and changed study protocol&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI symptom score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in GI symptom score with alanine &amp; placebo, when compared to the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fructose consumption</measure>
    <time_frame>4 weeks</time_frame>
    <description>Estimated daily consumption of fructose during the alanine &amp; placebo phases, when compared to baseline using prospective food diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath hydrogen and methane</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in Breath hydrogen and/or methane values with Alanine and Placebo when compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-12)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in SF-12 scores between baseline and after alanine and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Dietary Fructose Intolerance</condition>
  <arm_group>
    <arm_group_label>L-alanine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume l-alanine prior to eating fructose-containing foods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will consume the placebo prior to eating fructose-containing foods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>supplemental L-alanine</intervention_name>
    <description>Subjects will consume l-alanine prior to eating fructose-containing foods.</description>
    <arm_group_label>L-alanine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metamucil</intervention_name>
    <description>Subjects will consume the placebo prior to eating fructose-containing foods.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-99 years&#xD;
&#xD;
          2. Diagnosis of fructose malabsorption (positive breath test after ingestion of 25 grams&#xD;
             of fructose defined as either (a) ≥ 20 ppm rise of breath H2/CH4/both over baseline&#xD;
             values or a successive rise of ≥ 5 ppm over baseline and in 3 consecutive breath&#xD;
             samples)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cognitive impairment or any other inability to provide informed consent&#xD;
&#xD;
          2. Prisoners&#xD;
&#xD;
          3. GI surgery except appendectomy, cholecystectomy, caesarean section, hysterectomy&#xD;
&#xD;
          4. Antibiotics in the previous 6 weeks&#xD;
&#xD;
          5. History of bacterial overgrowth or lactose intolerance&#xD;
&#xD;
          6. Major co-morbid illnesses, including chronic pancreatitis, celiac disease,&#xD;
             inflammatory bowel disease, diabetes, scleroderma, pseudo-obstruction syndromes etc.&#xD;
&#xD;
          7. Known food allergies&#xD;
&#xD;
          8. Medication use: opioids, Tegaserod, laxatives, enemas&#xD;
&#xD;
          9. An allergy or intolerance to any fiber supplements or other dietary nutritional&#xD;
             supplements such as: psyllium (Metamucil), Maltodextrin, Citric Acid, and&#xD;
             methylcellulose (Citrucel).&#xD;
&#xD;
         10. Difficulty swallowing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Satish Rao</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fructose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

